Director, Blade Therapeutics

Jim Scopa

Role	Organisation	Sources
Director	Blade Therapeutics	OneVentures portfolio

Coverage

Stories naming Jim Scopa. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

US biotech heavyweights join OneVentures

OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.

OneVentures portfolio Sat 4 May 2019 BiVACOR OneVentures Biomedical Translation Fund Blade Therapeutics Johnson & Johnson Stanford Dr Dan Baker Jim Scopa Dr Paul Kelly

Something wrong? Tell us

Jim Scopa

Roles

Coverage

US biotech heavyweights join OneVentures